MITZI TYRE: Open Payments
NPI 1396983227 · WAYCROSS, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,280 in 35 payments from 11 companies in 2025. Trend: 2023 $171 · 2024 $260 · 2025 $1,280
Food & beverage: $1,280
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 6 | $272 |
| E.R. Squibb & Sons, L.L.C. | 8 | $267 |
| ABBVIE INC. | 4 | $173 |
| Axsome Therapeutics, Inc. | 2 | $144 |
| Vanda Pharmaceuticals Inc. | 3 | $110 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $102 |
| Otsuka America Pharmaceutical, Inc. | 4 | $89 |
| Supernus Pharmaceuticals, Inc. | 2 | $45 |
| Janssen Pharmaceuticals, Inc | 2 | $30 |
| Indivior Inc. | 1 | $25 |
Products named: INGREZZA, COBENFY, VRAYLAR, Auvelity, FANAPT, CAPLYTA, REXULTI, Qelbree.
Industry payments across GA — which companies pay providers there.
